Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
Yonsei Medical Journal
;
: 695-698, 2011.
Article
in English
| WPRIM
| ID: wpr-33245
ABSTRACT
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quinazolines
/
Sigmoid Diseases
/
Intestinal Fistula
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Intestinal Perforation
/
Antineoplastic Agents
Limits:
Aged
/
Female
/
Humans
Language:
English
Journal:
Yonsei Medical Journal
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS